dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
dexamethasone sustained-release (TLC599) / Taiwan Liposome Company, Endo
OPEAXE, ChiCTR2000036080: Evaluation of the efficacy of dexamethasone sustained-release implant (Ozurdex) in patients with proliferative diabetic retinopathy complicated with diabetic macular edema (vitrectomy / silicone oil filling and silicone oil removal) in combination

Not yet recruiting
4
200
 
Intraoperative dexamethasone sustained release implant ;none
Beijing aier intech eye hospital; Beijing aier intech eye hospital, Self-financing
Diabetic retinopathy
 
 

Download Options